WO1996015262A3 - Method for the detection of ras oncogenes, in particular the 12-ras oncogene - Google Patents

Method for the detection of ras oncogenes, in particular the 12-ras oncogene Download PDF

Info

Publication number
WO1996015262A3
WO1996015262A3 PCT/GB1995/002644 GB9502644W WO9615262A3 WO 1996015262 A3 WO1996015262 A3 WO 1996015262A3 GB 9502644 W GB9502644 W GB 9502644W WO 9615262 A3 WO9615262 A3 WO 9615262A3
Authority
WO
WIPO (PCT)
Prior art keywords
pct
ras
restriction site
ras oncogene
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1995/002644
Other languages
French (fr)
Other versions
WO1996015262A2 (en
Inventor
Jarle Breivik
Gustav Gaudernack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinnova SF
Original Assignee
Medinnova SF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinnova SF filed Critical Medinnova SF
Priority to AT95936662T priority Critical patent/ATE213276T1/en
Priority to EP95936662A priority patent/EP0791074B1/en
Priority to DE69525468T priority patent/DE69525468D1/en
Priority to US08/836,329 priority patent/US6090546A/en
Priority to JP8515836A priority patent/JPH10508746A/en
Priority to AU38514/95A priority patent/AU704784B2/en
Publication of WO1996015262A2 publication Critical patent/WO1996015262A2/en
Publication of WO1996015262A3 publication Critical patent/WO1996015262A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Led Device Packages (AREA)
  • Debugging And Monitoring (AREA)

Abstract

PCT No. PCT/GB95/02644 Sec. 371 Date Aug. 22, 1997 Sec. 102(e) Date Aug. 22, 1997 PCT Filed Nov. 10, 1995 PCT Pub. No. WO96/15262 PCT Pub. Date May 23, 1996The invention relates to an oligonucleotide primer sequence for use in in vitro amplification, characterised in that said primer sequence is capable of creating a BstX I restriction site overlapping codon (12) and/or an Xcm I restriction site overlapping codon (13) or a Bce 83I restriction site overlapping codon (61) of the wild-type K-ras oncogene, methods of using said primer sequences for detecting activating mutations in codons (12 and/or 13 and/or 61) of the K-ras oncogene and kits for performing the methods.
PCT/GB1995/002644 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the 12-ras oncogene Ceased WO1996015262A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT95936662T ATE213276T1 (en) 1994-11-11 1995-11-10 METHOD FOR DETECTING RAS ONCOGENES, IN PARTICULAR THE K-RAS ONCOGEN
EP95936662A EP0791074B1 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the k-ras ancogene
DE69525468T DE69525468D1 (en) 1994-11-11 1995-11-10 METHOD FOR DETECTING RAS ONCOGENES, IN PARTICULAR THE K-RAS ONCOGEN
US08/836,329 US6090546A (en) 1994-11-11 1995-11-10 Method for the detection of Ras oncogenes, in particular the K-ras oncogene
JP8515836A JPH10508746A (en) 1994-11-11 1995-11-10 Method for detecting ras oncogene, especially K-ras oncogene
AU38514/95A AU704784B2 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the K-ras oncogene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9422814.5 1994-11-11
GB9422814A GB9422814D0 (en) 1994-11-11 1994-11-11 Chemical method

Publications (2)

Publication Number Publication Date
WO1996015262A2 WO1996015262A2 (en) 1996-05-23
WO1996015262A3 true WO1996015262A3 (en) 1996-08-15

Family

ID=10764263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/002644 Ceased WO1996015262A2 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the 12-ras oncogene

Country Status (9)

Country Link
US (1) US6090546A (en)
EP (1) EP0791074B1 (en)
JP (1) JPH10508746A (en)
AT (1) ATE213276T1 (en)
AU (1) AU704784B2 (en)
CA (1) CA2205017A1 (en)
DE (1) DE69525468D1 (en)
GB (1) GB9422814D0 (en)
WO (1) WO1996015262A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7132519B2 (en) 1996-12-10 2006-11-07 Sequenom, Inc. Releasable nonvolatile mass-label molecules
US7198893B1 (en) 1996-11-06 2007-04-03 Sequenom, Inc. DNA diagnostics based on mass spectrometry

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
US6780583B1 (en) 1996-07-19 2004-08-24 Board Of Trustees Operating Michigan State University DNA encoding canine von willebrand factor and methods of use
US6767707B2 (en) 1996-07-19 2004-07-27 University Of Michigan DNA encoding canine von willebrand factor and methods of use
DE69734247T2 (en) * 1996-07-19 2006-06-22 The Regents Of The University Of Michigan, Ann Arbor FOR THE DNA CURLED BY WILLEBRAND FACTOR OF THE DOGS AND METHOD FOR THEIR USE
US6410237B1 (en) 1997-07-18 2002-06-25 Board Of Trustees Operating Michigan State University DNA encoding canine von Willebrand factor and methods of use
DE19736691A1 (en) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Characterising and identifying disseminated metastatic cancer cells
US7014994B1 (en) 1999-03-19 2006-03-21 Cornell Research Foundation,Inc. Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process
JP4601830B2 (en) * 1999-03-19 2010-12-22 コーネル リサーチ ファンデーション インク． Coupled polymerase chain reaction-restriction endonuclease digestion-ligase detection reaction method
WO2000066783A2 (en) * 1999-05-04 2000-11-09 Ortho-Clinical Diagnostics, Inc. Rapid and efficient capture of dna from sample without using cell lysing reagent
US7262006B1 (en) 2000-05-01 2007-08-28 Ortho-Clinical Diagnostics, Inc. Rapid and efficient capture of DNA from sample without using cell lysing reagent
JP4914990B2 (en) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド Therapeutic composition for protecting animals from cancer
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR20070068460A (en) * 2004-10-18 2007-06-29 글로브이뮨 Yeast System Treatment for Chronic Hepatitis C
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
DE102008029356A1 (en) * 2008-06-20 2009-12-24 Siemens Healthcare Diagnostics Gmbh Process for the purification of nucleic acids, in particular from fixed tissue
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc Immunotherapy for chronic hepatitis c virus infection
CN101381779B (en) * 2008-10-21 2011-06-08 广州益善生物技术有限公司 Detection probe of kRas gene mutation, liquid phase chip and detection method thereof
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
DE102008061714A1 (en) * 2008-12-12 2010-06-17 Siemens Healthcare Diagnostics Inc., Deerfield Process for the purification of nucleic acids, in particular from fixed tissue
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
EP4313110A4 (en) * 2021-03-22 2025-06-25 The Johns Hopkins University K-RAS INHIBITOR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466083A2 (en) * 1990-07-09 1992-01-15 E.R. SQUIBB & SONS, INC. Method for site-directed mutagenesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (en) * 1982-04-23 1987-03-11 Sintef PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES.
KR920700360A (en) * 1989-03-22 1992-02-19 하리크 프리드리히 Sliding bearing
JPH04235919A (en) * 1991-01-17 1992-08-25 Sankyo Co Ltd Anticancer drug
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
DE69205657T2 (en) * 1991-10-11 1996-06-13 Squibb & Sons Inc Use of biphosphonates in the manufacture of a medicament for blocking neoplastic cell transformations caused by Ras oncogenes.
GB9323305D0 (en) * 1993-11-11 1994-01-05 Medinnova Sf Isoaltion of nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466083A2 (en) * 1990-07-09 1992-01-15 E.R. SQUIBB & SONS, INC. Method for site-directed mutagenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACOBSON D ET AL: "Rapid nonradioactive screening for activating ras oncogene mutations using PCR-primer introduced restriction analysis (PCR-PIRA)", PCR METHODS AND APPLICATIONS, vol. 1, no. 2, 1991, pages 146 - 48, XP000572412 *
LIN S ET AL: "mutation analysis of K-ras oncogenes in gasteroenterologic cancers by the amplified created restriction sites method", AM. J. CLIN. PATHOL, vol. 100, no. 6, December 1993 (1993-12-01), pages 686 - 89, XP000572107 *
MITSUDOMI T ET AL: "Mutations of ras genes distinguish a subset of non-small-cell lung cancer lines from small-cell cancer cell lines", ONCOGENE, vol. 6, no. 8, 1991, pages 1353 - 62, XP002004427 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7419787B2 (en) 1995-03-17 2008-09-02 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7198893B1 (en) 1996-11-06 2007-04-03 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US7501251B2 (en) 1996-11-06 2009-03-10 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US7132519B2 (en) 1996-12-10 2006-11-07 Sequenom, Inc. Releasable nonvolatile mass-label molecules

Also Published As

Publication number Publication date
AU704784B2 (en) 1999-05-06
EP0791074B1 (en) 2002-02-13
CA2205017A1 (en) 1996-05-23
EP0791074A2 (en) 1997-08-27
DE69525468D1 (en) 2002-03-21
GB9422814D0 (en) 1995-01-04
JPH10508746A (en) 1998-09-02
ATE213276T1 (en) 2002-02-15
WO1996015262A2 (en) 1996-05-23
US6090546A (en) 2000-07-18
AU3851495A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
AU3851495A (en) Method for the detection of ras oncogenes, in particular the K-ras oncogene
DE3853678D1 (en) METHOD FOR DETECTING THE CARCINOGENIC HUMAN PAPILLOMAVIRUS.
DE69332642D1 (en) METHODS FOR DETECTING MICROMETASAS IN PROSTATE CANCER
DE69812838T2 (en) Composition and method for inhibiting the growth of microorganisms based on stabilized sodium hypobromite and isothiazolones
ATE197479T1 (en) METHOD FOR DUPLICATION OF NUCLEIC ACID SEQUENCES
GB9015845D0 (en) Diagnostic method
PT1246835E (en) Substituted sapogenins and their use
DE59611481D1 (en) Chromatin-regulatorgene
HU9602106D0 (en) Hiv protease inhibitors and intermediates
DE69729145D1 (en) Reagent and method for inhibiting N-RAS expression
ATE260678T1 (en) METHOD FOR DETECTING ENDOMETRIOSIS
DE69328025D1 (en) DORSAL TISSUE INFLUENCING FACTOR AND COMPOSITIONS
AU2135497A (en) Genetic markers and methods for the detection of escherichia coli serotype-0157:h7
ATE332371T1 (en) COMPOSITIONS AND METHODS FOR HIGHER SENSITIVITY AND SPECIFICITY OF NUCLEIC ACID SYNTHESIS
DE69506704D1 (en) METHOD AND SAMPLES FOR DETECTING MARKERS ASSOCIATED WITH THE LOCUS OF INFANTILE SPINALAMYOTROPHIES
AU2174392A (en) Adn sequences of the human papillomavirus type 42, and diagnostic application thereof
Oppenheim et al. Regulation of protein synthesis in bacteriophage λ restoration of gene expression in λN− strains by mutations in the cro gene
ATE488601T1 (en) NUCLEOTIDE SEQUENCES FOR DETECTION OF ENTEROHEMORRRHAGIC ESCHERICHIA COLI
PL330227A1 (en) Method of obtaining phenylheterocyclic compounds suitable as cox-2 inhibitors
NO20021196L (en) A method for detecting oxidized forms of guanylate cyclase and a method for screening dexterity activators of soluble guanylate cyclase with oxide inhibitor iron
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
MY132876A (en) Method for visually demonstrating the effectiveness of an anti-bacteria attachment composition
DE69635025D1 (en) NEW PROCEDURE FOR THE DETECTION OF CRYPTOSPORIDIUM
DE69701867D1 (en) METHOD FOR DETECTING ANTIBODIES AGAINST HAV 3C PROTEINASE
Hershberger Mechanisms for activation of transcription initiation at the P (RM) promoter of bacteriophage lambda

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2205017

Country of ref document: CA

Ref country code: CA

Ref document number: 2205017

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995936662

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08836329

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995936662

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995936662

Country of ref document: EP